# TMEM52B

## Overview
TMEM52B is a gene that encodes the transmembrane protein 52B, which is involved in various cellular processes, particularly in the context of cancer biology. As a transmembrane protein, TMEM52B plays a critical role in modulating cell signaling pathways by interacting with key proteins such as E-cadherin and the epidermal growth factor receptor (EGFR). The protein's ability to stabilize E-cadherin and regulate EGFR activity underscores its importance in maintaining cellular adhesion and controlling signaling pathways that influence cancer cell survival and invasion (Lee2021TMEM52B). TMEM52B's function as a tumor suppressor is further highlighted by its association with improved patient survival in several cancer types, making it a potential prognostic marker and therapeutic target (Lee2021TMEM52B).

## Clinical Significance
The TMEM52B gene has been implicated in various cancers due to its role in modulating cancer cell survival and invasion. Suppression of TMEM52B is associated with the promotion of epithelial-mesenchymal transition (EMT), increased tumor growth, and early metastasis. This suppression enhances the activation and internalization of the epidermal growth factor receptor (EGFR), which activates downstream signaling pathways such as ERK1/2, JNK, and AKT, promoting cancer cell survival and invasion (Lee2021TMEM52B). 

Clinical data suggest that high TMEM52B expression correlates with increased patient survival in several cancers, including breast, lung, kidney, and rectal cancers. Conversely, decreased TMEM52B expression is linked to poor survival outcomes, particularly in renal cell carcinoma and gastric cancer, indicating its potential role in renal carcinogenesis and increased invasiveness in gastric cancer (Lee2021TMEM52B). 

TMEM52B's role as a tumor suppressor is further supported by its ability to stabilize E-cadherin, a protein crucial for cell-cell adhesion. Loss of TMEM52B leads to the generation of soluble E-cadherin fragments that activate EGFR, contributing to cancer progression (Lee2021TMEM52B). These findings highlight TMEM52B as a potential prognostic marker and therapeutic target in cancer treatment strategies.

## Interactions
TMEM52B interacts with E-cadherin, a key protein involved in cell adhesion. TMEM52B enhances the stability of E-cadherin by binding to it, which prevents its degradation and shedding. This interaction is crucial for maintaining E-cadherin levels and function in cells (Lee2021TMEM52B). The suppression of TMEM52B leads to the generation of a soluble E-cadherin fragment, which contributes to the activation of the epidermal growth factor receptor (EGFR) (Lee2021TMEM52B).

TMEM52B also influences EGFR activity. Its suppression results in increased EGFR phosphorylation and internalization, which enhances downstream signaling pathways such as MAPKs and AKT, promoting cancer cell survival and invasion (Lee2021TMEM52B). TMEM52B overexpression, on the other hand, reduces EGFR phosphorylation and the activation of these pathways, indicating a regulatory role in EGFR signaling (Lee2021TMEM52B).

Additionally, TMEM52B affects β-catenin activity. Its suppression enhances β-catenin transcriptional activity by altering its phosphorylation and promoting its nuclear transport (Lee2021TMEM52B). These interactions highlight TMEM52B's role in modulating key signaling pathways involved in cancer cell behavior.


## References


[1. (Lee2021TMEM52B) Yunhee Lee, Dongjoon Ko, Junghwa Yoon, Younghoon Lee, and Semi Kim. Tmem52b suppression promotes cancer cell survival and invasion through modulating e-cadherin stability and egfr activity. Journal of Experimental &amp; Clinical Cancer Research, March 2021. URL: http://dx.doi.org/10.1186/s13046-021-01828-7, doi:10.1186/s13046-021-01828-7. This article has 11 citations.](https://doi.org/10.1186/s13046-021-01828-7)